Niagen 2025 Q2 Earnings Record Net Income Surges 24,160%

Niagen (NAGE) delivered strong earnings results for Q2 2025, exceeding expectations with a sharp turnaround in profitability. The company reported a net income of $3.61 million, representing a 24,160% increase from a $15,000 loss in the prior-year period. In line with this performance, the company raised its full-year sales guidance from 20%–25% to 22%–27% year-over-year growth.

Revenue
Total revenue reached $31.12 million in Q2 2025, a 36.8% increase compared to the same quarter in 2024. The Consumer Products segment led the revenue growth with $22.70 million, while the Ingredients segment contributed $7.62 million. Additionally, the Analytical Reference Standards and Services segment generated $799,000, marking a notable contribution to the total. The Corporate and other segment reported $0 in revenue.

Earnings/Net Income
Niagen returned to profitability with an EPS of $0.05 in Q2 2025, reversing from a $0.00 loss in the prior-year quarter. The company posted a record net income of $3.61 million, marking a dramatic 24,160% improvement from a net loss of $15,000 in Q2 2024 and its highest Q2 net income in 13 years.

Price Action
The stock price of Niagen edged up 1.95% during the latest trading day but declined 1.36% during the most recent full trading week. It has, however, plummeted 24.44% month-to-date.

Post-Earnings Price Action Review
A strategy of purchasing Niagen shares immediately after its earnings report and holding for 30 days has historically yielded strong returns, achieving a 57.54% return over the past three years—46.20% above the benchmark. This approach has shown a Sharpe ratio of 5.32, indicating a favorable risk-adjusted return. Despite a maximum drawdown of 0.00%, the strategy faced high volatility of 67.71%, suggesting significant market fluctuations.

CEO Commentary
Niagen Bioscience CEO Rob Fried highlighted a strong second quarter, with net sales reaching $31.1 million, up 37% year-over-year, and net income of $3.6 million. Fried emphasized the company’s leadership in the NAD+ market, continued execution, and strategic investments in growth while maintaining profitability. He noted recent clinical progress in Parkinson’s disease and the expansion of premium partnerships, including a luxury hospitality launch, expressing optimism about the company’s future.

Guidance
The company raised its full-year 2025 net sales outlook to 22%–27% year-over-year growth, reflecting strong execution and market leadership. This revised guidance aligns with ongoing operational momentum, including expanded clinic availability and clinical trial data expected in 2026.

Additional News
On August 5, 2025, Niagen Bioscience announced its Q2 2025 earnings report. While no detailed earnings metrics were disclosed at that time, the report emphasized the company’s commitment to advancing regulated therapeutic applications and expanding its market presence. The announcement marked a key update in the company's strategic positioning and operational progress.